Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Developmental therapeutics

4548 - Precision Medicine: Preliminary Results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) Study.


28 Sep 2019


Poster Discussion – Developmental therapeutics


Apostolia Maria Tsimberidou


Annals of Oncology (2019) 30 (suppl_5): v159-v193. 10.1093/annonc/mdz244


A.M. Tsimberidou1, D.S. Hong2, S. Fu3, D. Karp4, S.A. Piha-Paul5, M. Kies6, V. Ravi7, V. Subbiah8, S. Patel9, S. Tu10, F. Janku8, J. Heymach11, A. Johnson12, L. Zhao13, J. Zhang13, D.A. Berry14, D. Vining15, A. Futreal13, V.A. Miller16, F. Meric-Bernstam8

Author affiliations

  • 1 Investigatonal Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Department Of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston/US
  • 4 Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, TX 77030 - Houston/US
  • 5 Department Of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 77030 - Houston/US
  • 6 Thoracic, Head And Neck Medical Oncology, MD Anderson, 77030 - Houston/US
  • 7 Department Of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 8 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 9 Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 10 Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 11 The University Of Texas Md Anderson Cancer Center, Thoracic/head & Neck Medical Oncology, MD Anderson, 77030 - texas/US
  • 12 Ipct, MD Anderson, 77030 - Houston/US
  • 13 Genomic Medicine, MD Anderson, 77030 - Houston/US
  • 14 Biostatistics, MD Anderson, 77030 - Houston/US
  • 15 Diagnostic Imaging, MD Anderson, 77030 - Houston/US
  • 16 Clinical Development, Foundation Medicine, 02141 - Cambridge/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4548


Precision medicine is associated with favorable outcomes in selected patients. We initiated IMPACT 2, a randomized study to compare PFS in patients with metastatic cancer treated on the basis of tumor genomic profiling results vs. those whose treatment was not selected based on genomic analysis. Herein, we assessed the association between patient characteristics and overall survival (OS).


Patients with advanced, metastatic cancer underwent tumor biopsy and genomic profiling (Foundation One). Variants were filtered to eliminate germline mutations (annotation, ANNOVAR) and artifacts. Patients were presented at tumor board and were randomized if they met criteria for clinical trials. OS was measured from enrollment on study until last follow-up or death from any cause.


From 5/2014 to 4/2017, 320 of 391 enrolled patients completed tumor profiling. Baseline characteristics (n = 320) were as follows: men, 47%; median age, 63 yrs (range, 25-83); performance status 1, 88%; median no. of prior therapies, 3 (range, 0-14); liver metastases, 40%; albumin < 3.5 g/L, 12%; LDH > 618 IU/L, 29%; platelet count > or < the normal limits, 15%. Most common tumor types were head and neck, 19%; gastrointestinal, 16%; and lung, 11%. Most frequently mutated genes: TP53, 42%; KRAS,16%; PIK3CA,12%; and CDKN2A, 11%. Of 320 patients, 69 (22%) were randomized; of the remaining 251 patients, 153 (61%) received other treatment (investigational or standard). Results of multivariate analyses for OS are displayed below.Table:


Multivariate analysis, OS
Risk FactorHR95% CIP
Age ≥ 60 yrs1.021.00-1.03.009
Liver metastases1.431.07-1.91.02
LDH > 618 IU/L2.191.61-2.97< .0001
Albumin < 3.5 g/dL1.901.26-2.87.002
KRAS mutated2.271.57-3.28< .0001
TP53 mutated1.381.04-1.84.03


In patients with metastatic cancer, age < 60 yrs, absence of liver metastases, normal albumin and LDH levels, and absence of KRAS or TP53 mutations were independent factors predicting longer OS. We demonstrated the feasibility of molecular profiling using newly obtained tumor biopsies and treating patients prospectively. The study is ongoing. Outcomes for randomized patients are awaited upon completion of the study.

Clinical trial identification

www.clinicaltrials.gov NCT02152254, First posted June 2, 2014.

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Foundation Medicine.


A.M. Tsimberidou: Research grant / Funding (institution): IMMATICS; Research grant / Funding (institution): Tempus; Research grant / Funding (institution): Parker Institute for Cancer Immunotherapy; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Baxalta; Research grant / Funding (institution): Foundation Medicine; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): Placon Therapeutics; Research grant / Funding (institution): Karus Therapeutics; Research grant / Funding (institution): Tvardi; Research grant / Funding (institution): OBI Pharma; Advisory / Consultancy: Roche, Europe; Advisory / Consultancy: Covance; Advisory / Consultancy: Genentech. D.S. Hong: Research grant / Funding (self): Adaptimmune; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Daichi-Sanko; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Genmab; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Infinity; Research grant / Funding (institution): Kite; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): LOXO; Research grant / Funding (institution): Mirati; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Medimmune; Research grant / Funding (institution): Molecular Template; Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.